These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

712 related items for PubMed ID: 17951208

  • 21. Nonalcoholic fatty liver disease and the metabolic syndrome.
    Marchesini G, Babini M.
    Minerva Cardioangiol; 2006 Apr; 54(2):229-39. PubMed ID: 16778754
    [Abstract] [Full Text] [Related]

  • 22. [Non-alcoholic fatty liver].
    Tagle Arrospide M.
    Rev Gastroenterol Peru; 2003 Apr; 23(1):49-57. PubMed ID: 12768215
    [Abstract] [Full Text] [Related]

  • 23. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
    Rafiq N, Younossi ZM.
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
    [Abstract] [Full Text] [Related]

  • 24. Fibrosis in alcoholic and nonalcoholic steatohepatitis.
    Bataller R, Rombouts K, Altamirano J, Marra F.
    Best Pract Res Clin Gastroenterol; 2011 Apr; 25(2):231-44. PubMed ID: 21497741
    [Abstract] [Full Text] [Related]

  • 25. Nonalcoholic steatohepatitis and the metabolic syndrome.
    Jiang J, Torok N.
    Metab Syndr Relat Disord; 2008 Mar; 6(1):1-7. PubMed ID: 18370830
    [Abstract] [Full Text] [Related]

  • 26. Mechanisms of disease progression in nonalcoholic fatty liver disease.
    Jou J, Choi SS, Diehl AM.
    Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
    [Abstract] [Full Text] [Related]

  • 27. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC, Berk PD.
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [Abstract] [Full Text] [Related]

  • 28. The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
    Sanderson SO, Smyrk TC.
    Am J Clin Pathol; 2005 Apr; 123(4):503-9. PubMed ID: 15743753
    [Abstract] [Full Text] [Related]

  • 29. Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease.
    Sanyal AJ.
    Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):46-53. PubMed ID: 16265100
    [Abstract] [Full Text] [Related]

  • 30. From the metabolic syndrome to NAFLD or vice versa?
    Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G.
    Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
    [Abstract] [Full Text] [Related]

  • 31. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.
    Kang H, Greenson JK, Omo JT, Chao C, Peterman D, Anderson L, Foess-Wood L, Sherbondy MA, Conjeevaram HS.
    Am J Gastroenterol; 2006 Oct; 101(10):2247-53. PubMed ID: 17032189
    [Abstract] [Full Text] [Related]

  • 32. Nonalcoholic fatty liver disease: a practical approach to evaluation and management.
    Rafiq N, Younossi ZM.
    Clin Liver Dis; 2009 May; 13(2):249-66. PubMed ID: 19442917
    [Abstract] [Full Text] [Related]

  • 33. Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis.
    Bosserhoff A, Hellerbrand C.
    Dig Dis; 2011 May; 29(4):377-83. PubMed ID: 21894008
    [Abstract] [Full Text] [Related]

  • 34. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
    Sasaki Y, Shimada T, Iizuka S, Suzuki W, Makihara H, Teraoka R, Tsuneyama K, Hokao R, Aburada M.
    Eur J Pharmacol; 2011 Jul 15; 662(1-3):1-8. PubMed ID: 21549692
    [Abstract] [Full Text] [Related]

  • 35. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease.
    Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA.
    Am J Gastroenterol; 2001 Oct 15; 96(10):2957-61. PubMed ID: 11693332
    [Abstract] [Full Text] [Related]

  • 36. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist's perspective.
    Lackner C.
    Expert Rev Gastroenterol Hepatol; 2011 Apr 15; 5(2):223-31. PubMed ID: 21476917
    [Abstract] [Full Text] [Related]

  • 37. Recent concepts in non-alcoholic fatty liver disease.
    Adams LA, Angulo P.
    Diabet Med; 2005 Sep 15; 22(9):1129-33. PubMed ID: 16108837
    [Abstract] [Full Text] [Related]

  • 38. Fatty liver and the metabolic syndrome.
    Neuschwander-Tetri BA.
    Curr Opin Gastroenterol; 2007 Mar 15; 23(2):193-8. PubMed ID: 17268250
    [Abstract] [Full Text] [Related]

  • 39. Histological assessment of non-alcoholic fatty liver disease.
    Hübscher SG.
    Histopathology; 2006 Nov 15; 49(5):450-65. PubMed ID: 17064291
    [Abstract] [Full Text] [Related]

  • 40. Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications.
    Tsochatzis EA, Manolakopoulos S, Papatheodoridis GV, Archimandritis AJ.
    Scand J Gastroenterol; 2009 Nov 15; 44(1):6-14. PubMed ID: 18661429
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 36.